Chemclin Diagnostics(SH:688468)2026-01-28 08:00Financial Performance Forecast - The company expects a net profit attributable to shareholders of RMB 40 million to 48 million for the year 2025, representing a year-on-year decrease of 62.23% to 68.52% compared to the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be RMB 26 million to 32 million, reflecting a year-on-year decline of 68.23% to 74.19%[3]. - In 2024, the company reported a total profit of RMB 137.92 million and a net profit attributable to shareholders of RMB 127.07 million[5]. - The financial data in the earnings forecast is preliminary and has not been audited by external accountants[10]. - Investors are advised to pay attention to investment risks as the final financial data will be disclosed in the audited annual report for 2025[11]. R&D and Innovation Strategy - The company maintains a high level of R&D investment to enhance core competitiveness despite the pressure on product prices due to industry-wide procurement policies[7]. - The company emphasizes a long-term operational philosophy focused on leading technology and innovative products to serve human health[9]. - The company is committed to a dual-driven strategy of import substitution and clinical interactive innovation using its proprietary LiCA® technology platform[9]. - The company aims to strengthen cost management and respond proactively to industry changes to build core competitiveness and achieve sustainable high-quality development[9]. Impact of External Factors - The reduction in government subsidies and other non-recurring gains compared to the previous year has impacted the financial performance[9].